PeptideOS
← Library

Adipotide

Pro-apoptotic peptidomimetic (anti-angiogenic, white adipose tissue)

Also known as: FTPP, Prohibitin-targeting peptide-1 (PTP-1), CKGGRAKDC-GG-D(KLAKLAK)2

Tier 3, Preclinical only

Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.

Half-life
Not established

No validated human or animal half-life located in an allowed primary source. Reported to have a short circulating half-life; not quantified from a citable primary source here.

Dosing
No established dose

Dosed by body weight in the primate study: 0.43 mg/kg subcutaneously once daily for 28 days in obese rhesus macaques. Kept as mg/kg per instructions; no back-calculation to a fixed mcg dose. No established human dose.

Regulatory status
Not approved. Preclinical; human clinical development reported to have been discontinued after early-phase evaluation due to a narrow therapeutic window (dose-dependent renal tubular effects).
Evidence base
animal only · confidence: low

Single influential non-human primate study (Science Translational Medicine 2011, available via PMC) plus rodent work; no controlled human efficacy/PK data in allowed sources.

Safety

Preclinical safety signal: dose-dependent (reversible) renal proximal tubule changes in monkeys. Narrow therapeutic window is the principal cited barrier to human use. No approved safety profile.

Sources